RxDoctor Payments Data

William Suarez, MD

General Practice · Kissimmee, FLNPI 1780636605

Payments from drug & device makers

$431in general payments, 2019–2025

Across 23 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$60
  • Bayer$53
  • Exact Sciences$45
  • Lilly USA, LLC$38
  • Pfizer$37
  • Novo Nordisk$33
  • plus $163 from 7 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$431 in reported general payments places this provider in the 60th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$7,862
Medicare patients
31
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$62,685
EliquisApixaban32$47,366
FarxigaDapagliflozin Propanediol40$46,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$44,726
JanuviaSitagliptin Phosphate42$39,937
TrulicityDulaglutide33$37,857
JardianceEmpagliflozin24$33,008
EntrestoSacubitril/Valsartan24$18,523
XareltoRivaroxaban15$14,983
Bydureon BciseExenatide Microspheres15$12,665
Breo ElliptaFluticasone/Vilanterol13$7,467
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,024
SymbicortBudesonide/Formoterol Fumarate14$3,824
Albuterol Sulfate HfaAlbuterol Sulfate128$2,815
Novolog FlexpenInsulin Aspart12$2,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$33$62,68556 claims
AstraZenecaFarxiga, Symbicort$60$50,37754 claims
PfizerEliquis$37$47,36632 claims
Lilly USA, LLCTrulicity$38$37,85733 claims
Johnson & JohnsonXarelto$31$14,98315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,901 general practice providers in Florida.

Other general practice in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →